Skip to main content

Table 2 Clinicopathological characteristics of 342 metastatic breast cancer patients (MBC) with or without hand-foot syndrome (HFS)

From: Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

Characteristic Total [cases (%)] Patients with HFS [cases (%)] Patients without HFS [cases (%)]
Age (years)
 ≤ 40 57 (16.7) 30 (8.8) 27 (7.9)
 > 40 285 (83.3) 163 (47.7) 122 (35.7)
Family history of cancera
 None 275 (80.4) 152 (44.4) 123 (36.0)
 Breast cancer or ovarian cancer 19 (5.6) 8 (2.3) 11 (3.2)
 Other malignancies 48 (14.0) 33 (9.6) 15 (4.4)
Menstrual station
 Premenopause 218 (63.7) 120 (35.1) 98 (28.7)
 Postmenopause 118 (34.5) 71 (20.8) 47 (13.7)
 Unclear 6 (1.8) 2 (0.6) 4 (1.2)
Clinical stage
 I + II 154 (45.0) 89 (26.0) 65 (19.0)
 III 143 (41.8) 85 (24.9) 58 (17.0)
 IV 14 (4.1) 5 (1.5) 9 (2.6)
 Unclear 31 (9.1) 14 (4.1) 17 (5.0)
Pathological type
 Intraductal carcinoma 4 (1.2) 2 (0.6) 2 (0.6)
 Infiltrating ductal carcinoma 306 (89.5) 172 (50.3) 134 (39.2)
 Invasive lobular carcinoma 17 (5.0) 11 (3.2) 6 (1.8)
 Others 11 (3.2) 7 (2.0) 4 (1.2)
 Unclear 4 (1.2) 1 (0.3) 3 (0.9)
Pathological grade
 Grade 1 10 (2.9) 8 (2.3) 2 (0.6)
 Grade 2–3 170 (49.7) 96 (28.1) 74 (21.6)
 Unclear 162 (47.4) 89 (26.0) 73 (21.3)
Vascular invasion
 No 308 (90.1) 174 (50.9) 134 (39.2)
 Yes 34 (9.9) 19 (5.6) 15 (4.4)
Axillary lymph node metastasis at initial diagnosis
 No 106 (31.0) 54 (15.8) 52 (15.2)
 Yes 225 (65.8) 136 (39.8) 89 (26.0)
 Unclear 11 (3.2) 3 (0.9) 8 (2.3)
Distant metastasis at initial diagnosis
 No 324 (94.7) 186 (54.4) 138 (40.4)
 Yes 14 (4.1) 5 (1.5) 9 (2.6)
 Unclear 4 (1.2) 2 (0.6) 2 (0.6)
ER status
 Positive 215 (62.9) 123 (36.0) 92 (26.9)
 Negative 117 (34.2) 65 (19.0) 52 (15.2)
 Unclear 10 (2.9) 5 (1.5) 5 (1.5)
PR status
 Positive 213 (62.3) 117 (34.2) 96 (28.1)
 Negative 118 (34.5) 70 (20.5) 48 (14.0)
 Unclear 11 (3.2) 6 (1.8) 5 (1.5)
HER2 status
 Positive 83 (24.3) 47 (13.7) 36 (10.5)
 Negative 230 (67.3) 130 (38.0) 100 (29.2)
 Unclearb 29 (8.5) 16 (4.7) 13 (3.8)
Therapy
 Capecitabine 20 (5.8) 10 (2.9) 10 (2.9)
 Docetaxel plus capecitabine 205 (59.9) 123 (36.0) 82 (24.0)
 Vinorelbine plus capecitabine 98 (28.7) 48 (14.0) 50 (14.6)
 Othersc 19 (5.6) 12 (3.5) 7 (2.0)
Therapy line
 First-line 211 (61.7) 121 (35.4) 90 (26.3)
 Multi-line 131 (38.3) 72 (21.1) 59 (17.3)
Metastatic site
 No visceral metastasis (including local recurrence) 104 (30.4) 60 (17.5) 44 (12.9)
 Visceral metastasis 238 (69.6) 133 (38.9) 105 (30.7)
Maintenance therapy
 Yes 137 (40.1) 94 (27.5) 43 (12.6)
 No 205 (59.9) 99 (28.9) 106 (31.0)
Response evaluation
 CR 7 (2.0) 5 (1.5) 2 (0.6)
 PR 194 (56.7) 107 (31.3) 87 (25.4)
 SD 90 (26.3) 56 (16.4) 34 (9.9)
 PD 39 (11.4) 20 (5.8) 19 (5.6)
 Unclear 12 (3.5) 5 (1.5) 7 (2.0)
Survival conditiond
 Alive 218 (63.7) 124 (36.3) 94 (27.5)
 Dead 124 (36.3) 69 (20.2) 55 (16.1)
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, CR complete response, PR partial response, SD stable disease, PD progressive disease
  2. aBreast cancer or ovarian cancer or other malignances of first- or second-degree relatives
  3. bEquivocal results (HER2++) without fluorescence in situ hybridization testing
  4. cOther capecitabine-based therapies
  5. dPatients’ survival conditions by last follow-up
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us